Baker Bros. Advisors TRDA Position
Active3-Fund ConvergenceBaker Bros. Advisors increased their position in Entrada Therapeutics, Inc. (TRDA) in Q4 2025, holding $52.1M worth of shares across 5,072,730 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
TRDA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ENTR-601-45 in 1052 days (Mar 1, 2029), making the timing of Baker Bros.'s position particularly relevant.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
4.4%
4.1 days to cover
Baker Bros. Advisors TRDA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 5,072,730 | +206,911 | $52.1M |
| Q3 2025 | Held | 4,865,819 | — | $28.2M |
| Q2 2025 | Held | 4,865,819 | — | $32.7M |
| Q1 2025 | Held | 4,865,819 | — | $44.0M |
| Q4 2024 | Held | 4,865,819 | — | $84.1M |
| Q3 2024 | Held | 4,865,819 | — | $77.8M |
| Q2 2024 | Held | 4,865,819 | — | $69.3M |
| Q1 2024 | Held | 4,865,819 | — | $68.9M |
| Q4 2023 | Held | 4,865,819 | — | $73.4M |
| Q3 2023 | Held | 4,865,819 | — | $76.9M |
| Q2 2023 | Held | 4,865,819 | — | $73.7M |
| Q1 2023 | New | 4,865,819 | +4,865,819 | $70.6M |
Frequently Asked Questions
Does Baker Bros. Advisors own TRDA?
Yes. As of Q4 2025, Baker Bros. Advisors holds 5,072,730 shares of Entrada Therapeutics, Inc. (TRDA) valued at $52.1M. This data comes from their SEC 13F filing.
How many hedge funds own TRDA?
3 specialist biotech hedge funds currently hold TRDA, including Redmile Group, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy TRDA?
Baker Bros. Advisors's position in TRDA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's TRDA position increasing or decreasing?
Baker Bros. Advisors increased their TRDA position in the most recent quarter, adding 206,911 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TRDACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →